2019年5月7日,

Promethera生物科学公司,全球创新者在细胞的药物和肝脏疾病,今天宣布关闭€3970万(JPY4.94十亿)系列D融资。圆是由日本新投资者共同伊藤忠公司,谁贡献€1000万年1月,这个融资和新生银行资本合作伙伴。MEDIPAL控股公司(日本),未来资产资本(韩国),家庭办公室六个雪(卢森堡),韩国投资合作伙伴(韩国),Ci: z投资LLP(日本)加入圆以及比利时的私人投资者。Promethera现有的投资者,三井& Co .)全球投资公司(MGI)也参加了融资。所得资金将加速公司的持续HepaStem ACLF临床项目和公司的第一个临床试验在纳什。此外,资金将用于生产扩大,临床项目和公司的整体运营和集团。“金融支持我们的新的和现有的投资者,以他们的经验在细胞疗法和广泛的亚洲和全球网络,将极大地帮助我们有效地推进世界上第一个细胞治疗ACLF,纳什通过临床试验,”约翰·Tchelingerian说Promethera博士,总裁兼首席执行官。“我们在后期的临床试验纳什将很快启动第一个在欧洲,预计将扩大到美国和亚洲。我们兴奋地看到HepaStem的候选药物可以改变严重肝病患者的生命。总的来说,我们看我们公司的转型时期,融资使我们在一个伟大的位置来执行我们的计划。” “Promethera has taken great steps to increase and bolster our relations and operations in Asia, and specifically in Japan and Korea, so we can benefit from the openness to stem-cell therapeutics in this area of the world,” said Mutsuki Takano, Group CFO and General Manager of Promethera’s Japan branch. “This territorial move has already started showing results, with our shareholder base growing significantly in Asia not least through this financing round.” HepaStem consists of liver stem cells that are obtained from ethically donated healthy human livers and expanded under cGMP conditions in production. The product candidate is currently being evaluated in a phase 2a clinical trial in the indication ACLF with first safety and efficacy results being presented recently at The International Liver Congress 2019 (EASL) as part of a late-breaking oral presentation. In addition to its cell-based approaches, HepaStem and H2Stem, Promethera is advancing a portfolio of complementary biologics approaches including the anti-TNF-R1 antibody Atrosimab. About Promethera Biosciences Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline (HepaStem and H2Stem), we develop antibody technologies such as the anti-TNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland). Promethera®, HepaStem®, H2stem® are all registered trademarks of the PROMETHERA group. View source version on businesswire.com: https://www.businesswire.com/news/home/20190506005807/en/ Promethera Biosciences SA